Orthofix International N.V. (NASDAQ:OFIX) – Gabelli raised their FY2017 earnings per share estimates for Orthofix International N.V. in a report issued on Wednesday, according to Zacks Investment Research. Gabelli analyst J. Tsai now anticipates that the medical device company will earn $1.60 per share for the year, up from their previous forecast of $1.55. Gabelli also issued estimates for Orthofix International N.V.’s FY2018 earnings at $1.80 EPS, FY2019 earnings at $2.00 EPS and FY2021 earnings at $2.35 EPS.
Several other equities research analysts have also weighed in on the company. BidaskClub lowered Orthofix International N.V. from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Zacks Investment Research lowered Orthofix International N.V. from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 11th. TheStreet lowered Orthofix International N.V. from a “b” rating to a “c+” rating in a research note on Tuesday, October 31st. BTIG Research set a $56.00 price target on Orthofix International N.V. and gave the company a “buy” rating in a research note on Monday, October 30th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $55.00 price objective (up previously from $50.00) on shares of Orthofix International N.V. in a report on Thursday, August 10th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $54.42.
WARNING: This story was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://ledgergazette.com/2017/11/13/orthofix-international-nv-expected-to-post-fy2017-earnings-of-1-60-per-share-ofix.html.
Shares of Orthofix International N.V. (OFIX) opened at $51.44 on Thursday. Orthofix International N.V. has a 1 year low of $32.51 and a 1 year high of $54.33. The company has a market capitalization of $937.80, a PE ratio of 33.62, a price-to-earnings-growth ratio of 2.55 and a beta of 0.15.
Orthofix International N.V. (NASDAQ:OFIX) last issued its quarterly earnings results on Monday, October 30th. The medical device company reported $0.42 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.01. The firm had revenue of $105.30 million for the quarter, compared to analysts’ expectations of $100.67 million. Orthofix International N.V. had a return on equity of 10.26% and a net margin of 0.33%. Orthofix International N.V.’s revenue was up 6.9% on a year-over-year basis. During the same quarter last year, the business posted $0.36 EPS.
Institutional investors and hedge funds have recently modified their holdings of the business. Pinebridge Investments L.P. boosted its stake in shares of Orthofix International N.V. by 2.3% in the 2nd quarter. Pinebridge Investments L.P. now owns 2,378 shares of the medical device company’s stock worth $111,000 after buying an additional 53 shares during the last quarter. State of Alaska Department of Revenue lifted its stake in Orthofix International N.V. by 79.3% in the second quarter. State of Alaska Department of Revenue now owns 3,551 shares of the medical device company’s stock valued at $165,000 after purchasing an additional 1,571 shares during the last quarter. Municipal Employees Retirement System of Michigan purchased a new position in Orthofix International N.V. in the second quarter valued at approximately $196,000. UBS Asset Management Americas Inc. purchased a new stake in shares of Orthofix International N.V. during the first quarter worth $229,000. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Orthofix International N.V. during the third quarter worth $315,000. 92.81% of the stock is owned by hedge funds and other institutional investors.
In other news, CFO Rice Doug sold 7,353 shares of Orthofix International N.V. stock in a transaction on Monday, September 11th. The stock was sold at an average price of $49.46, for a total value of $363,679.38. Following the transaction, the chief financial officer now owns 44,743 shares in the company, valued at approximately $2,212,988.78. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Luke T. Faulstick sold 4,800 shares of the firm’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $51.22, for a total value of $245,856.00. Following the sale, the director now directly owns 7,729 shares in the company, valued at approximately $395,879.38. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,842 shares of company stock valued at $1,084,897. Insiders own 5.60% of the company’s stock.
About Orthofix International N.V.
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.